BR9608799B1 - análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica. - Google Patents

análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.

Info

Publication number
BR9608799B1
BR9608799B1 BRPI9608799-4A BR9608799A BR9608799B1 BR 9608799 B1 BR9608799 B1 BR 9608799B1 BR 9608799 A BR9608799 A BR 9608799A BR 9608799 B1 BR9608799 B1 BR 9608799B1
Authority
BR
Brazil
Prior art keywords
pro
grf
fatty body
increased biological
pharmaceutical formulation
Prior art date
Application number
BRPI9608799-4A
Other languages
English (en)
Other versions
BR9608799A (pt
Inventor
Michel Ibea
Thierry Abribat
Paul Brazeau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27036979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9608799(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR9608799A publication Critical patent/BR9608799A/pt
Publication of BR9608799B1 publication Critical patent/BR9608799B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
BRPI9608799-4A 1995-05-26 1996-05-22 análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica. BR9608799B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45306795A 1995-05-26 1995-05-26
US65164596A 1996-05-22 1996-05-22
PCT/CA1996/000327 WO1996037514A1 (en) 1995-05-26 1996-05-22 Chimeric fatty body-pro-grf analogs with increased biological potency

Publications (2)

Publication Number Publication Date
BR9608799A BR9608799A (pt) 1999-12-07
BR9608799B1 true BR9608799B1 (pt) 2009-12-01

Family

ID=27036979

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9608799-4A BR9608799B1 (pt) 1995-05-26 1996-05-22 análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.
BRPI9608799A BRPI9608799B8 (pt) 1995-05-26 1996-05-22 análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI9608799A BRPI9608799B8 (pt) 1995-05-26 1996-05-22 análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.

Country Status (13)

Country Link
US (2) US5861379A (pt)
EP (1) EP0828758B1 (pt)
JP (1) JP3576170B2 (pt)
KR (1) KR100543190B1 (pt)
AT (1) ATE204881T1 (pt)
AU (1) AU697119B2 (pt)
BR (2) BR9608799B1 (pt)
CA (1) CA2222068C (pt)
DE (1) DE69614849T2 (pt)
DK (1) DK0828758T3 (pt)
ES (1) ES2163020T3 (pt)
PT (1) PT828758E (pt)
WO (1) WO1996037514A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020311A (en) * 1995-05-26 2000-02-01 Theratechnologies, Inc. GRF analogs with increased biological potency
US6458764B1 (en) * 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
BR0001606A (pt) * 1999-04-12 2001-04-24 Pfizer Prod Inc Composições de hormÈnio de crescimento e de hormÈnio de liberação de hormÈnio de crescimento
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
EP1282437B1 (en) 2000-05-16 2008-03-19 Genentech, Inc. Treatment of cartilage disorders
WO2002010195A2 (en) * 2000-08-02 2002-02-07 Theratechnologies Inc. Modified peptides with increased potency
EP1205551A1 (en) * 2000-11-09 2002-05-15 Pfizer Products Inc. Growth hormone and growth hormone releasing hormone compositions
FR2851461B1 (fr) * 2003-02-21 2007-04-20 Seppic Sa Utilisation de n-octanoyl aminoacides comme actif cosmetique et pharmaceutique amincissant
AU2003229222B2 (en) * 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
CA2538342C (en) 2003-09-12 2013-01-08 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency
WO2005037307A1 (en) * 2003-10-20 2005-04-28 Theratechnologies Inc. Use of growth hormone releasing factor analogs in treating patients suffering from wasting
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
US20100267635A1 (en) * 2009-04-20 2010-10-21 Theratechonolgies Inc. Use of protease inhibitors and grf molecules in combination therapy
US20100267636A1 (en) * 2009-04-20 2010-10-21 Theratechnologies Inc. Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy
WO2012021876A2 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2616095A4 (en) * 2010-09-16 2014-03-19 Univ Miami ACCELERATING WOUND HEALING WITH HORMONE FOR RELEASE OF GROWTH HORMONE AND AGONISTS
CN103547591A (zh) 2011-04-21 2014-01-29 瑟瑞技术公司 生长激素释放因子(grf)类似物及其用途
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
ES2817877T3 (es) 2012-02-15 2021-04-08 Aileron Therapeutics Inc Macrociclos peptidomiméticos
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN102702343A (zh) * 2012-06-14 2012-10-03 吉尔生化（上海）有限公司 一种固相合成替莫瑞林的方法
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
US8871713B2 (en) 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
PT3445778T (pt) 2016-04-19 2020-10-15 Griffon Pharmaceuticals Int Sa C/O Biopole Sa Péptidos bioativos peguilados e suas utilizações
WO2024091863A1 (en) * 2022-10-25 2024-05-02 Starrock Pharma Llc Combinatorial, and rotational combinatorial therapies for obesity and other diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622312A (en) * 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
CA1271600A (en) * 1985-01-07 1990-07-10 David Howard Coy Growth hormone-releasing peptides and method of treating mammals therewith
US4870054A (en) * 1985-09-27 1989-09-26 Recker Robert R Treatment for osteoporosis using GRF or a biologically active analog thereof
DE3742633A1 (de) * 1987-12-16 1989-06-29 Hoechst Ag Peptide mit beeinflussender wirkung auf die hypophyse von saeugern
IL86102A (en) * 1987-05-11 1994-04-12 Univ Tulane Alkylated peptides that release growth hormone and their use
FR2622455B1 (fr) * 1987-11-04 1991-07-12 Agronomique Inst Nat Rech Application du facteur de stimulation de la secretion de l'hormone de croissance humaine, de ses fragments actifs et des analogues correspondants, pour augmenter la production laitiere et le poids des nouveau-nes chez les mammiferes
US5065748A (en) * 1989-11-14 1991-11-19 University Of South Florida Method of diagnosing growth hormone disorders employing somatostatin and growth hormone releasing hormone
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
ZA922746B (en) * 1991-04-26 1992-12-30 Lilly Co Eli Superactive grf analogs

Also Published As

Publication number Publication date
CA2222068C (en) 2007-04-10
BRPI9608799B8 (pt) 2019-11-05
AU697119B2 (en) 1998-09-24
EP0828758B1 (en) 2001-08-29
JP3576170B2 (ja) 2004-10-13
EP0828758A1 (en) 1998-03-18
CA2222068A1 (en) 1996-11-28
US5939386A (en) 1999-08-17
PT828758E (pt) 2002-02-28
AU5683396A (en) 1996-12-11
KR19990021938A (ko) 1999-03-25
BR9608799A (pt) 1999-12-07
DE69614849D1 (de) 2001-10-04
WO1996037514A1 (en) 1996-11-28
MX9709098A (es) 1998-06-30
JPH11505807A (ja) 1999-05-25
DK0828758T3 (da) 2002-01-07
KR100543190B1 (ko) 2006-06-23
ATE204881T1 (de) 2001-09-15
ES2163020T3 (es) 2002-01-16
US5861379A (en) 1999-01-19
DE69614849T2 (de) 2002-05-16

Similar Documents

Publication Publication Date Title
BR9608799B1 (pt) análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.
ATE311453T1 (de) Grf-analoge mit erhöhter biologischer potenz
Vigneaud et al. The synthesis of an octapeptide amide with the hormonal activity of oxytocin
DE69434418D1 (de) Orale Dareichungsform
AU2000277238A1 (en) Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
IL102848A0 (en) Polypeptides having growth hormone releasing activity,their use and pharmaceutical compositions containing them
ATE76296T1 (de) Pharmazeutische zusammensetzung zur behandlung von akuter myocardischer ischaemie.
DE69025920D1 (de) Glykosaminoglykan-modifiertes Protein, Verfahren zu dessen Herstellung und pharmazeutische Zubereitungen, die es enthalten
DK193887D0 (da) Fysiologisk aktivt peptid
RU93005051A (ru) Способ получения катионных кристаллов гр или производных гр, катионные кристаллы человеческого гр или производных человеческого гр, фармацевтические препараты, использование процесса кристаллизации
DE3650358D1 (de) Diphosphonate enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Arthrosis.
GB1395090A (en) Stabilized hormone compositions
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
US3670079A (en) Anabolic agents
ES8700054A1 (es) Procedimiento de obtencion de germicidas a base de acidos clorhidrico y fosforico.
CA2073554A1 (en) Water-soluble composition for sustained-release
DE3771057D1 (de) Platin enthaltender cytostatischer wirkstoff.
ATE25708T1 (de) Biologisch aktive konjugate, ihre herstellung und ihre anwendung.
KR890014745A (ko) Fr-900493화합물과 그 제조방법 및 그를 함유한 의약조성물
ATE39697T1 (de) Erythromycin-a-salz mit mucosecretolytischer und fluidisierender aktivitaet, verfahren zu seiner herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
IT1233426B (it) Composizioni farmaceutiche per uso orale ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo, e procedimento per prepararle

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2009, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061560/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132356-33.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: THE SECRETARY OF STATE FOR DEFENCE, THE WELLCOME FOUNDATION LIMITED, THERATECHNOLOGIES INC, UNITED STATES GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE ARMY, UNIVERSITE DE MONTREAL.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.061560/2013-54 SECAO JUDICIARIA DO RIO DE JANEIRO 25A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO0132356-33.2013.4.02.5101APELADO: THE SECRETARY OF STATE FOR DEFENCE E OUTROS APELANTE: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI DECISAO: PELO EXPOSTO, DIVIRJO DO EXMO. RELATOR E DOU PROVIMENTO AO RECURSO DE APELACAO E JULGO PROCEDENTE O PEDIDO ALTERNATIVO, PARA DECLARAR A NULIDADE PARCIAL DAS PATENTES PI 9508392-8, PI 9607850-2, PI 9607851-0, PI 9608799-4, PI 9607752-2 E PI 9510423-2, E DETERMINAR A CORRECAO DE SEUS RESPECTIVOS PRAZOS DE VIGENCIA CONFORME TABELA A SEGUIR:PATENTE: PI 9508392-8 NOVO PRAZO DE VIGENCIA: 12/07/2015PATENTE: PI 9607850-2 NOVO PRAZO DE VIGENCIA

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2009, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A PUBLICACAO NA RPI 2034 DE 29.12.2009, QUANTO AO PRAZO DE VIGENCIA: ATE 22.05.2016, CONFORME DECISAO JUDICIAL PUBLICADA NA RPI 2547 DE 29.10.2019 - INPI 52400.061560/2013

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 22.05.2016, CONFORME DECISAO JUDICIAL